Investigating the impact of polysomy 17 in breast cancer patients with HER2 amplification through meta-analysis

Abstract

Abstract Objectives Since studies regarding the effect of polysomy 17 (P17) in breast cancer cases with some specific clinical findings are few in number and are in small sample sizes, meta-analysis was implemented to exhibit the effects of P17 in patients with Human Epidermal growth factor Receptor 2 (HER2) amplification on lymph node involvement and tumor grade. Materials and methods Pubmed literature database was scanned up to June 2017 by using the keywords “polysomy 17 breast cancer” and 141 studies were accessed. Ultimately four of the reviewed papers have been found to be appropriate for examining the effect of P17 on lymph node involvement and tumor grade. Prior to meta-analysis, publication bias and heterogeneity of the studies was examined. Results Meta-analysis in the examining the effect of polysomy 17 on lymph node involvement (OR=1.708, 95% CI: 1.068–2.733), on grade [3]/[3,1] (OR=3.402, 95% CI: 1.726–6.707), on grade [3]/[3, 2] (OR=2.581, 95% CI: 0.778–8.559) and on grade [2]/[2,1] (OR=1.854, 95% CI: 0.531–6.468) was determined in those with HER2 amplification. Conclusion It was observed that in terms of lymph node involvement, P17 was a risk factor in patients and with regard to tumor grade, P17 was a risk factor when grade increased in patients with amplification.